Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa

By sjmartinez • June 23, 2023

Beesham I, Milford C, Smit J, Joseph Davey DL, Baeten JM, Heffron R, Beksinska M, Mansoor LE. Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa. BMC Public Health. 2023 Jun 22;23(1):1210. doi: 10.1186/s12889-023-16139-z. PMID: 37349816.

Tags: Infectious Diseases, Oral pre-exposure prophylaxis, Post-trial access and use, Publications, south africa, young women

Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia

Dao KT, D'Assumpcao C, Sharma R, Singh C, Kuran R, Heidari A. Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia. Cureus. 2025 Feb 24;17(2):e79588.[...]

Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial

Giganti MJ, Chew KW, Moser C, Eron JJ, Pinilla M, Li JZ, Ritz J, Javan AC, Wohl DA, Daar ES, Currier JS, Smith DM, Hughes[...]

T cell immune senescence is associated with frailty and sarcopenia in lung transplant candidates

Schaenman JM, Pickering H, Reed EF, Rossetti M, Seligman B, Weigt SS, Shino M, Sayah D, Belperio J, Hu A, Prosper A, Ruchalski K, Ardehali[...]